Co-expansion of cytokine-induced killer cells and Vγ9Vδ2 T cells for CAR T-cell therapy

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Du, Shou Hui ^a   Li, Zhendong ^a   Chen, Can ^c   Tan, Wee Kiat ^a,b   Chi, Zhixia ^a   Kwang, Timothy Weixin ^c   Xu, Xue Hu ^d   Wang, Shu ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^c Tessa Therapeutics   (Singapore)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CD3 ANTIBODY; CD64 ANTIGEN; CD86 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; ZOLEDRONIC ACID; CARCINOEMBRYONIC ANTIGEN; CD137 ANTIGEN; CD19 ANTIGEN; CD19 MOLECULE, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL EXPANSION; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; CYTOTOXICITY; ELECTROPORATION; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RAJI CELL LINE; T LYMPHOCYTE SUBPOPULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BURKITT LYMPHOMA; CELL PROLIFERATION; CYTOLOGY; DRUG SCREENING; FEEDER CELL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; K-562 CELL LINE; MORTALITY; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; SURVIVAL ANALYSIS; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD137; ANTIGENS, CD19; ANTIGENS, CD86; BURKITT LYMPHOMA; CARCINOEMBRYONIC ANTIGEN; CELL PROLIFERATION; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FEEDER CELLS; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; MICE; PRIMARY CELL CULTURE; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991823787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161820     Document Type: Article

References (37)

1. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230):62-8. doi: 10.1126/science.aaa4967 PMID: 25838374.
2. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2010; 37(5):1191-7. doi: 10.1016/j.ejcts.2009.11.051 PMID: 20137969.
3. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematological oncology. 2009; 27 (3):130-9. doi: 10.1002/hon.886 PMID: 19294626.
4. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert opinion on biological therapy. 2012; 12(6):673-84. doi: 10.1517/14712598.2012. 675323 PMID: 22500889.
5. Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, et al. Thymoglobulin, interferongamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. Journal of translational medicine. 2010; 8:129. doi: 10.1186/1479-5876-8-129 PMID: 21138560.
6. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. British journal of haematology. 2002; 116(1):78-86. doi: 10.1046/j.1365-2141.2002.03247.x PMID: 11841399.
7. Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, Duangsa-ard S, Sa-ngiamsuntorn K, Hongeng S, et al. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3(+)CD56(+) subset through the co-culturing dendritic cells. PloS One. 2013; 8(11):e78980. doi: 10.1371/journal.pone.0078980 PMID: 24232460.
8. Zhang J, Zhu L, Wei J, Liu L, Yin Y, Gu Y, et al. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. Journal of cancer research and clinical oncology. 2012; 138(6):1057-62. doi: 10.1007/s00432-012-1179-1 PMID: 22392076.
9. Legut M, Cole DK, Sewell AK. The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy. Cellular & molecular immunology. 2015; 12(6):656-68. doi: 10.1038/cmi. 2015.28 PMID: 25864915.
10. Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, et al. What lessons can be learned from gamma delta T cell-based cancer immunotherapy trials? Cellular & molecular immunology. 2013; 10(1):35-41. doi: 10.1038/cmi.2012.39 PMID: 23241899.
11. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of gamma delta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer immunology, immunotherapy: CII. 2011; 60(8):1075-84. doi: 10.1007/s00262-011-1021-7 PMID: 21519826.
12. Gogoi D, Chiplunkar SV. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. The Indian journal of medical research. 2013; 138(5):755-61. PMID: 24434328.
13. Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, et al. Intraperitoneal injection of in vitro expanded Vgamma9Vdelta2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer medicine. 2014; 3(2):362-75. doi: 10.1002/cam4.196 PMID: 24515916.
14. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gamma delta T cells to immunology. Nature reviews Immunology. 2013; 13(2):88-100. doi: 10.1038/nri3384 PMID: 23348415.
15. Shirasu N, Yamada H, Shibaguchi H, Kuroki M, Kuroki M. Corrigendum to "Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM". Biomed Res Int. 2015; 292436. doi: 10.1155/2015/292436 PMID: 25715100.
16. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. PMID: 1350088
17. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, et al. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(13):4232-40. doi: 10.1158/1078-0432.CCR-07-4912 PMID: 18594005.
18. Agrati C, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi MR, et al. Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. International immunology. 2006; 18(1):11-8. doi: 10.1093/intimm/dxh337 PMID: 16361319.
19. Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, et al. Expansion of human peripheral blood gammadelta T cells using zoledronate. Journal of visualized experiments: JoVE. 2011;(55). doi: 10.3791/3182 PMID: 21931292.
20. Rischer M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. British journal of haematology. 2004; 126 (4):583-92. doi: 10.1111/j.1365-2141.2004.05077.x PMID: 15287953.
21. Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Human immunology. 2006; 67(11):863-73. doi: 10.1016/j.humimm.2006.08.292 PMID: 17145366.
22. Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010; 95(12):2144-52. doi: 10.3324/haematol. 2010.026310 PMID: 20713459.
23. Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21(12):2268-77. doi: 10.1038/mt.2013.192 PMID: 23985696.
24. Lopez RD, Waller EK, Lu PH, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer immunology, immunotherapy: CII. 2001; 49 (12):629-40. doi: 10.1007/s002620000148 PMID: 11258789.
25. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. Journal of immunology. 1988; 140(12):4245-52. PMID: 2967332.
26. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014; 20 (22):5708-19. PMID: 24833662
27. Deniger DC, Moyes JS, Cooper LJ. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol. 2014; 5:636. doi: 10.3389/fimmu.2014.00636 PMID: 25566249
28. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer research. 2008; 68(8):2961-71. doi: 10.1158/0008-5472.CAN-07-5600 PMID: 18413766.
29. Li Y, Kurlander RJ. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. Journal of translational medicine. 2010; 8:104. doi: 10.1186/1479-5876-8-104 PMID: 20977748.
30. Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. Journal of immunological methods. 2011; 366(1-2):43-51. doi: 10.1016/j.jim.2011.01.002 PMID: 21255579.
31. Butler MO, Hirano N. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunological reviews. 2014; 257(1):191-209. doi: 10.1111/imr.12129 PMID: 24329798.
32. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Molecular therapy: the journal of the American Society of Gene Therapy. 2007; 15(5):981-8. doi: 10.1038/mt.sj.6300134 PMID: 17375070.
33. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8(8):793-800. doi: 10.1038/nm730 PMID: 12091876.
34. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. Journal of immunology. 2007; 179(7):4910-8. doi: 10.4049/jimmunol.179.7.4910 PMID: 17878391.
35. Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, et al. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clinical immunology. 2010; 137(2):221-33. doi: 10.1016/j.clim. 2010.07.009 PMID: 20708974.
36. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological reviews. 2014; 257(1):107-26. doi: 10.1111/imr. 12131 PMID: 24329793.
37. Krug C, Wiesinger M, Abken H, Schuler-Thurner B, Schuler G, Dorrie J, et al. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer immunology, immunotherapy: CII. 2014; 63(10):999-1008. doi: 10.1007/s00262-014-1572-5 PMID: 24938475.